Emergent BioSolutions, Inc.
https://www.emergentbiosolutions.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Emergent BioSolutions, Inc.
OncoResponse Mines PD-1 Therapy “Elite Responders” For IO Breakthroughs
Emerging Company Profile: Harvesting blood and tissue samples from patients treated with PD-1 immunotherapy, OncoResponse is developing antibodies it believes can transform cold solid tumors into hot.
Tech Transfer Roundup: MD Anderson, Moffitt Lead Busy Academic Cancer Partnering Space
MD Anderson teams with Eisbach on precision oncology and with Yingli on a five-year translational research effort. Moffitt inks tie-ups with Dyve and Turnstone.
Smooth Sailing At US CDC Committee For Pfizer’s TicoVac, Emergent’s Vaxchora
Advisory Committee on Immunization Practices unanimously supports recommendations for Pfizer tick-borne encephalitis vaccine and pediatric use of Emergent’s cholera vaccine in travelers at risk of exposure.
The Quality Lowdown: Pandemic Inspection Results Trickle In As Investigators Venture Out
US FDA inspections lead to warning letters for Aurobindo and Health Plus, while Emergent BioSolutions site escapes nearly unscathed; Sun waits for Halol revisit and Jubilant suffers poor-quality costs as agency investigators resume domestic surveillance post-omicron.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
- Vaccines
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Adapt Pharma Limited
- Aptevo Therapeutics
- BioPort Corporation
- Cangene Corporation
- Trubion Pharmaceuticals, Inc.
- PaxVax Corporation